Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis.
Standard
Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis. / Schmitt-Rau, Karlheinz; Rosenbach, T; Radtke, Marc; Augustin, Matthias.
In: DERMATOLOGY, Vol. 221, No. 3, 3, 2010, p. 236-242.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cost-Effectiveness of Biological Therapy in Remission Induction of Moderate to Severe Plaque Psoriasis.
AU - Schmitt-Rau, Karlheinz
AU - Rosenbach, T
AU - Radtke, Marc
AU - Augustin, Matthias
PY - 2010
Y1 - 2010
N2 - Background: The introduction of biological agents has considerably changed the treatment of moderate to severe psoriasis. So far only limited data on their cost-effectiveness exist. Objective: Determination of the cost-effectiveness of biologicals from a German third payer's perspective, assessed over a 12-week period. Methods: Efficacies of the biologicals were determined by a literature review. Treatment modalities were taken from the European S3 psoriasis guideline. Costs were calculated on the basis of the German physicians' fee schedule. Cost-effectiveness was determined and a sensitivity analysis performed. Results: Infliximab at a dose of 3 mg/kg was the most cost-effective agent, directly followed by adalimumab, infliximab 5 mg/kg and ustekinumab. The least cost-effective agent was etanercept 2 × 50 mg/week. Sensitivity analysis showed considerable overlap of the cost-effectiveness ratios. Conclusion: Under the conditions of the German health care system, biological agents for psoriasis differ in their cost-effectiveness ratios. Differences are small, however. A major limitation of the study is the short time horizon of 12 weeks.
AB - Background: The introduction of biological agents has considerably changed the treatment of moderate to severe psoriasis. So far only limited data on their cost-effectiveness exist. Objective: Determination of the cost-effectiveness of biologicals from a German third payer's perspective, assessed over a 12-week period. Methods: Efficacies of the biologicals were determined by a literature review. Treatment modalities were taken from the European S3 psoriasis guideline. Costs were calculated on the basis of the German physicians' fee schedule. Cost-effectiveness was determined and a sensitivity analysis performed. Results: Infliximab at a dose of 3 mg/kg was the most cost-effective agent, directly followed by adalimumab, infliximab 5 mg/kg and ustekinumab. The least cost-effective agent was etanercept 2 × 50 mg/week. Sensitivity analysis showed considerable overlap of the cost-effectiveness ratios. Conclusion: Under the conditions of the German health care system, biological agents for psoriasis differ in their cost-effectiveness ratios. Differences are small, however. A major limitation of the study is the short time horizon of 12 weeks.
M3 - SCORING: Zeitschriftenaufsatz
VL - 221
SP - 236
EP - 242
JO - DERMATOLOGY
JF - DERMATOLOGY
SN - 1018-8665
IS - 3
M1 - 3
ER -
